Rethinking Antibody-Drug Conjugates
Following the recent success of two conjugates, companies are focused on developing the next generation of the cancer technology
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
June 18, 2012 Cover
Volume 90, Issue 25
Following the recent success of two conjugates, companies are focused on developing the next generation of the cancer technology
Cover image:
Credit:
Following the recent success of two conjugates, companies are focused on developing the next generation of the cancer technology
Latest estimates of longer time and higher cost reflect conservative approach, not trouble
Controversial theory of flavor pairing seeks to illuminate why foods go together well
As current as smartphones, as eternal as ancient Chinese tea sets, glass enjoys a clear advantage in many applications
Sale of carbon credits is windfall for companies, but heady days are coming to an end
Documentary filmmakers explore the human side of the periodic table
Computational method identifies side-effect targets completely unrelated to therapeutic targets